GWAS
2015-11-09
A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Replicated
493
Participants
N/A
Studies